119 related articles for article (PubMed ID: 26637276)
21. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
22. Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages.
Wang DH; Lee HS; Yoon D; Berry G; Wheeler TM; Sugarbaker DJ; Kheradmand F; Engleman E; Burt BM
Clin Cancer Res; 2017 Feb; 23(3):778-788. PubMed ID: 27496865
[TBL] [Abstract][Full Text] [Related]
23. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
Friess T; Scheuer W; Hasmann M
Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
[TBL] [Abstract][Full Text] [Related]
24. A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer.
Sacher AG; Le LW; Lara-Guerra H; Waddell TK; Sakashita S; Chen Z; Kim L; Zhang T; Kamel-Reid S; Salvarrey A; Darling G; Yasufuku K; Keshavjee S; de Perrot M; Shepherd FA; Liu G; Tsao MS; Leighl NB
Oncotarget; 2016 May; 7(18):25632-9. PubMed ID: 27028852
[TBL] [Abstract][Full Text] [Related]
25. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
26. Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.
Schöttle J; Chatterjee S; Volz C; Siobal M; Florin A; Rokitta D; Hinze Y; Dietlein F; Plenker D; König K; Albus K; Heuckmann JM; Rauh D; Franz T; Neumaier B; Fuhr U; Heukamp LC; Ullrich RT
Oncotarget; 2015 Nov; 6(36):38458-68. PubMed ID: 26540572
[TBL] [Abstract][Full Text] [Related]
27. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
[TBL] [Abstract][Full Text] [Related]
28. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Friess T; Scheuer W; Hasmann M
Clin Cancer Res; 2005 Jul; 11(14):5300-9. PubMed ID: 16033849
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Kelly K; Altorki NK; Eberhardt WE; O'Brien ME; Spigel DR; Crinò L; Tsai CM; Kim JH; Cho EK; Hoffman PC; Orlov SV; Serwatowski P; Wang J; Foley MA; Horan JD; Shepherd FA
J Clin Oncol; 2015 Dec; 33(34):4007-14. PubMed ID: 26324372
[TBL] [Abstract][Full Text] [Related]
31. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
32. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Kahraman D; Holstein A; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Dietlein M; Wolf J; Kobe C
Clin Nucl Med; 2012 Nov; 37(11):1058-64. PubMed ID: 23027207
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
34. Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes.
Hu Y; Dong XZ; Liu X; Liu P; Chen YB
Mol Pharm; 2016 Feb; 13(2):689-97. PubMed ID: 26685983
[TBL] [Abstract][Full Text] [Related]
35. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.
Gandara DR; Mack PC; Bult C; Li T; Lara PN; Riess JW; Astrow SH; Gandour-Edwards R; Cooke DT; Yoneda KY; Moore EH; Pan CX; Burich RA; David EA; Keck JG; Airhart S; Goodwin N; de Vere White RW; Liu ET
Clin Lung Cancer; 2015 May; 16(3):165-72. PubMed ID: 25838158
[TBL] [Abstract][Full Text] [Related]
36. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
Crvenkova S; Ivkovski Lj; Dimovski A; Kaeva B
Prilozi; 2012; 33(1):303-11. PubMed ID: 22983065
[TBL] [Abstract][Full Text] [Related]
38. Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
Monnet I; Audigier-Valette C; Girard N; Vergnenègre A; Molinier O; Souquet PJ; Blanchon F; Bonnetain F; Taguieva-Pioger N; Lamour C; Wislez M
Lung Cancer; 2016 Aug; 98():84-90. PubMed ID: 27393512
[TBL] [Abstract][Full Text] [Related]
39. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
Spigel DR; Edelman MJ; O'Byrne K; Paz-Ares L; Mocci S; Phan S; Shames DS; Smith D; Yu W; Paton VE; Mok T
J Clin Oncol; 2017 Feb; 35(4):412-420. PubMed ID: 27937096
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV
J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]